SGP SpyGlass Pharma, Inc.

CIK 0001778922 8 ready 8-Ks latest October 19, 2026, 4:10 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 8

Latest filing October 19, 2026, 4:10 PM ET

Top materiality 0.90

Event mix other_material ×3 · earnings ×3 · m_and_a ×1

Sentiment 5 pos · 0 neg · 3 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for SGP

Highest-materiality recent filing

SpyGlass Pharma closes IPO, raises $172.5M at $16.00/share

February 9, 2026, 6:59 PM ET other material materiality 0.90 positive item 5.02 item 5.03 item 7.01 item 9.01 ◈ Governance Changes ×2

Closed IPO of 10,781,250 shares (incl. full exercise of underwriters' option for 1.4M additional shares) at $16.00/share.
Aggregate gross proceeds of $172.5 million before underwriting discounts and offering expenses.

Read filing →

October 19, 2026, 4:10 PM ET other material materiality 0.65 positive item 8.01 item 9.01

SpyGlass reports 4-year BIM-IOL data: 37% IOP cut, 86% off drops, no product-related AEs

Interim 4-year data in 21 evaluable patients: mean IOP fell 37% to 15.9 mmHg from 25.1 mmHg post-washout across 75/150/300 mcg dose groups.
October 1, 2026, 8:15 AM ET M&A materiality 0.82 positive item 7.01 item 8.01 item 9.01

SpyGlass Pharma acquires AVS from Santen for $13M to secure IOL supply

SpyGlass Pharma closed its acquisition of 100% of Advanced Vision Science (AVS) from Santen Holdings US on October 1, 2026, for a purchase price of $13,000,000 in cash.
August 6, 2026, 4:16 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

SpyGlass Pharma Q2 net loss $19.9M; cash $234.2M; Phase 3 enrollment on track

Net loss of $19.9M ($0.59 per share) vs $8.7M ($3.81) in Q2 2025.
May 14, 2026, 4:15 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

SpyGlass Pharma reports Q1 loss of $13.8M; Phase 1/2 BIM-IOL data shows 98% drop-free, 34% IOP reduction

Net loss of $13.8M ($0.69/share) vs $8.8M loss in Q1 2025; R&D expenses $8.5M, G&A $6.9M.
March 26, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

SpyGlass Pharma reports FY2025 net loss $39.9M; positive Phase 1/2 data and $172.5M IPO

Net loss of $12.6M in Q4 2025 ($5.72/sh) and $39.9M for FY2025 ($17.98/sh).
March 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

SpyGlass Pharma reports positive 12-month Phase 1/2 results for BIM-IOL System; 97% off topical drops

97% of patients on BIM-IOL System were free from all topical IOP-lowering medications at 12 months.
February 13, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 5.02

SpyGlass Pharma discloses FY2025 performance cash bonuses for named executive officers

Compensation Committee approved FY2025 bonuses on Feb 12, 2026.
February 9, 2026, 6:59 PM ET other material materiality 0.90 positive item 5.02 item 5.03 item 7.01 item 9.01 ◈ Governance Changes ×2

SpyGlass Pharma closes IPO, raises $172.5M at $16.00/share

Closed IPO of 10,781,250 shares (incl. full exercise of underwriters' option for 1.4M additional shares) at $16.00/share.

Earnings & guidance

2026-Q1 EPS reported -$0.69 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event other_material

5 positive 0 negative 3 neutral

source · SGP on sec.gov